VolitionRX Ltd (VNRX) Rating Reiterated by HC Wainwright

VolitionRX Ltd (NYSEMKT:VNRX)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Monday. They currently have a $10.00 target price on the medical research company’s stock. HC Wainwright’s price objective points to a potential upside of 175.48% from the stock’s current price.

VolitionRX (VNRX) traded up $0.24 during mid-day trading on Monday, reaching $3.63. 106,214 shares of the company traded hands, compared to its average volume of 47,499. VolitionRX has a 1 year low of $2.08 and a 1 year high of $5.45.

ILLEGAL ACTIVITY WARNING: This story was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.chaffeybreeze.com/2017/11/13/volitionrx-ltd-vnrx-rating-reiterated-by-hc-wainwright.html.

Several hedge funds have recently made changes to their positions in the company. Lagoda Investment Management L.P. grew its holdings in shares of VolitionRX by 7.4% in the 2nd quarter. Lagoda Investment Management L.P. now owns 3,155,692 shares of the medical research company’s stock valued at $11,171,000 after buying an additional 216,613 shares during the period. Leisure Capital Management acquired a new position in shares of VolitionRX in the 3rd quarter valued at $193,000. Finally, Bank of New York Mellon Corp grew its holdings in shares of VolitionRX by 177.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,376 shares of the medical research company’s stock valued at $108,000 after buying an additional 19,414 shares during the period.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Ratings for VolitionRX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply